報價延遲最少15分鐘:2025/04/15 14:49 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.205 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.50/-2.60
|
|
企業價值
225.82M
|
| 資產負債 |
|
每股賬面淨值
4.55
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/04/15 14:49 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Acelyrin Inc is a late-stage clinical biopharmaceutical company. The clinical biopharma segment researches and develops treatments for diseases with pathology related to excess activation of the immune system. It is focused on providing patients with life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. |